Five weeks prior to
initiating pembrolizumab, patients were given intralesional T - VEC injection at doses up to 4 mL per treatment (106 PFU / mL, then 108 PFU / mL every 2 weeks).
Not exact matches
UNC Lineberger researchers are planning to launch an investigator -
initiated clinical trial year to assess whether the combination denosumab with the checkpoint inhibitor
pembrolizumab is more effective than
pembrolizumab alone for treating patients with advanced melanoma.
Similarly, a combination phase Ib / II trial of PV - 10 and
pembrolizumab [27] has been
initiated in patients with stage IV melanoma.
Studies of PV - 10 with
pembrolizumab and of CVA21 with
pembrolizumab are also being
initiated.